Clinical Trial Update: A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites [Phase 1]

View source ↗

Summary

This is a Phase 1 study evaluating the safety, tolerability and immunological response of ASP2390 in adults with house dust mite allergy. The trial is active bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• House Dust Mite Allergy

Drugs mentioned

• ASP2390 (ASP2390)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Allergic to House Dust Mites | Phase 1 | Status: ACTIVE_NOT_RECRUITING